HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02696 HENLIUS

Trading 12-23 15:46:34

60.800

+0.450

+0.75%

High62.500	Low57.950	Vol455.20K
Open59.900	D1 Closing60.350	Amplitude7.54%
Mkt Cap33.04B	Tradable Cap9.94B	Total Shares543.49M
T/O27.13M	T/O Rate0.28%	Tradable Shares163.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"HENLIUS","latestPrice":60.8,"timestamp":1766475979541,"preClose":60.35,"halted":0,"volume":455200,"delay":0,"floatShares":163428541,"shares":543494853,"eps":1.6730090750851652,"marketStatus":"Trading","change":0.45,"latestTime":"12-23 15:46:34","open":59.9,"high":62.5,"low":57.95,"amount":27127050,"amplitude":0.075394,"askPrice":60.85,"askSize":1900,"bidPrice":60.8,"bidSize":900,"shortable":3,"etf":0,"ttmEps":1.680811038157015,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766477400000},"marketStatusCode":2,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":60.35,"openAndCloseTimeList":[[1766453400000,1766462400000],[1766466000000,1766476800000]],"volumeRatio":0.781549,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2593312312","title":"Shanghai Henlius Biotech (SEHK:2696) Valuation Check After US FDA IND Approval for HLX18 Biosimilar Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593312312","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593312312?lang=en_us&edition=fundamental","pubTime":"2025-12-21 09:27","pubTimestamp":1766280437,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (SEHK:2696) just cleared a key hurdle by securing US FDA approval of its IND for HLX18, a nivolumab biosimilar, which paves the way for phase 1 trials in multiple solid tumors.\nSee our latest analysis for Shanghai Henlius Biotech.\nThat HLX18 milestone lands after a busy year for Henlius, with HLX22 plus HLX87 also moving deeper into breast cancer trials. It comes despite a 90 day share price return of minus 19.39 percent and a still eye catching three year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-valuation-check-after-us-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-valuation-check-after-us-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","DCF","IND","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2592161786","title":"Henlius Biotech Gets US FDA Nod to Conduct Trial of Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2592161786","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592161786?lang=en_us&edition=fundamental","pubTime":"2025-12-19 20:31","pubTimestamp":1766147517,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech's  investigational new drug application for the phase 1 clinical trial of HLX18 was approved by the US Food and Drug Administration, a Friday Hong Kong bourse filing said.The firm intends to begin US trials of the drug, which has been developed to treat multiple solid tumors, when certain conditions are met.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"1129223645","title":"HENLIUS (02696): FDA Approves Phase 1 Clinical Trial Application for HLX18, a Nivolumab Biosimilar, for Treatment of Various Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1129223645","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129223645?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:08","pubTimestamp":1766135300,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Phase 1 clinical trials of HLX18, a self-developed nivolumab...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2592527431","title":"FDA Approves Shanghai Henlius Biotech's IND Application for Nivolumab Biosimilar HLX18 Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592527431","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592527431?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:03","pubTimestamp":1766135022,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that its investigational new drug application for a phase 1 clinical trial of HLX18, a nivolumab biosimilar , has been approved by the United States Food and Drug Administration . HLX18 is independently developed by Henlius for the treatment of multiple solid tumors. The company plans to initiate the clinical trial in the United States when conditions permit. No other organizations are mentioned as recipients of this regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 19, 2025, and is solely re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL4mw4c6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1230","BK1161","00656","02696"],"gpt_icon":0},{"id":"2592527381","title":"Shanghai Henlius Biotech Inc - Phase 1 Clinical Trial of Nivolumab Biosimilar Hlx18 Approved by United States FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2592527381","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592527381?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:01","pubTimestamp":1766134868,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XO17T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"2590057213","title":"BRIEF-Shanghai Henlius Biotech Says NDA For Hansizhuang Granted Priority Review By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2590057213","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590057213?lang=en_us&edition=fundamental","pubTime":"2025-12-12 17:40","pubTimestamp":1765532452,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Henlius Biotech Says NDA For Hansizhuang Granted Priority Review By NMPADec 12 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK:NDA FOR HANSIZHUANG GRANTED PRIORITY REVIEW BY NMPAFurther company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XH1DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"1158714296","title":"HENLIUS (02696): NDA for Hansizhuang® Combined with Chemotherapy in Gastric Cancer Neoadjuvant/Adjuvant Therapy Accepted by NMPA and Included in Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1158714296","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158714296?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:56","pubTimestamp":1765529788,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that the New Drug Application (NDA) for its self-developed Hansizhuang® (serplulimab injection) combined with platinum-based chemotherapy as neoadjuvant and adjuvant therapy...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2590719945","title":"Henlius Biotech's Serplulimab NDA for Gastric Cancer Combo Granted Priority Review by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2590719945","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590719945?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:48","pubTimestamp":1765529285,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that its New Drug Application  for HANSIZHUANG  in combination with chemotherapy for neo-/adjuvant treatment of gastric cancer has been accepted by the National Medical Products Administration  of China and has been granted priority review. This regulatory milestone follows the achievement of the primary endpoint in a Phase 3 clinical trial in mainland China. No other organizations were mentioned as recipients of this regulatory review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 12, 2025, and is solely res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL1YbQhN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","HK0000165453.HKD","02696","BK1161","BK1230"],"gpt_icon":0},{"id":"2590457193","title":"Shanghai Henlius Biotech Inc - Nda for Hansizhuang Granted Priority Review by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2590457193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590457193?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:46","pubTimestamp":1765529211,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XH1DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"1172386204","title":"HENLIUS (02696): Phase 2/3 Clinical Trial Applications for HLX22 Combined with HLX87 in HER2-Positive Breast Cancer First-Line Treatment and Neoadjuvant Therapy Approved by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1172386204","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172386204?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:24","pubTimestamp":1765272265,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that the National Medical Products Administration (NMPA) has approved the Phase 2/3 clinical trial applications for HLX22 (a recombinant humanized anti-HER2 monoclonal...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BC","BK4190","BK1161","02696"],"gpt_icon":0},{"id":"2590311384","title":"Shanghai Henlius Biotech Secures NMPA Approval for Phase 2/3 Trials of HLX22 and HLX87 in HER2-Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590311384","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590311384?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:15","pubTimestamp":1765271717,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that the National Medical Products Administration has approved applications for Phase 2/3 clinical trials of HLX22  in combination with HLX87  for the first-line treatment and neoadjuvant treatment of HER2-positive breast cancer. As of the announcement date, no similar combination has been approved for marketing globally. The approval marks a significant step forward in the company's oncology pipeline, but Henlius cautioned that successful development and commercialization of HLX22 and HLX87 cannot be guaranteed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service opera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL1L7tPm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","BK1161","BK1230","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2590311388","title":"Shanghai Henlius Biotech Inc - Nmpa Approves Phase 2/3 Trials for Hlx22 and Hlx87","url":"https://stock-news.laohu8.com/highlight/detail?id=2590311388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590311388?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:15","pubTimestamp":1765271704,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XE1D0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02696","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"2589338838","title":"Henlius Biotech's Breast Cancer Drug Included in China's Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589338838","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589338838?lang=en_us&edition=fundamental","pubTime":"2025-12-08 16:01","pubTimestamp":1765180912,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech  said its breast cander drug, FUTUONING, has been included in China's National Reimbursement Drug List, a Sunday Hong Kong bourse filing said.Shares of the drugmaker were down over 2% in Monday afternoon trading.The inclusion is for the indication of drug in combination with Fulvestrant for the treatment of adult patients with breast cancer who have experienced disease progression after prior endocrine therapy.The new edition of the list will become effective on Jan. 1, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"1129047194","title":"HENLIUS (02696): FULINNING® (Fulvestrant Citrate Capsules) Included in China's National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1129047194","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129047194?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:42","pubTimestamp":1765104168,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that FULINNING® (Fulvestrant Citrate Capsules) has been included in the 2025 National Reimbursement Drug List (NRDL) under Category B. The approved indication covers its use...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"2589037871","title":"Shanghai Henlius Biotech's FUTUONING Added to China's National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589037871","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589037871?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:25","pubTimestamp":1765103102,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that its product FUTUONING  has been included in Category B of the National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance  for 2025 in mainland China. The approval covers the use of FUTUONING in combination with Fulvestrant for the treatment of adult patients with hormone receptor positive and HER2 negative recurrent or metastatic breast cancer who have experienced disease progression after prior endocrine therapy. The updated NRDL will take effect from January 1, 2026, increasing patient access to FUTUONING and supporting the company's marketing and sales efforts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL2mHPQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","00656","BK1230","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"1182071381","title":"Shanghai Henlius (2696) Announces 2025 Fourth EGM and Seeks Approval for Sinopharm Distribution Framework Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=1182071381","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182071381?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:25","pubTimestamp":1764771900,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (the “Company,” Stock Code: 2696) has released a proxy form for its 2025 fourth extraordinary general meeting (EGM), scheduled for 31 December 2025 at 9:00 a.m. The EGM...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"1169492479","title":"Shanghai Henlius Biotech (2696) Announces EGM and Proposes New Distribution Framework with Sinopharm Group","url":"https://stock-news.laohu8.com/highlight/detail?id=1169492479","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169492479?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:06","pubTimestamp":1764770781,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (Stock Code: 2696) has issued a notice of its Extraordinary General Meeting (EGM) to be held on Wednesday, 31 December 2025, at 9:00 a.m. in Xuhui District, Shanghai....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"2588044653","title":"Shanghai Henlius Biotech Inc. Announces Date for 2025 Fourth Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588044653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588044653?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:06","pubTimestamp":1764770763,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. has scheduled its 2025 Fourth Extraordinary General Meeting for 31 December 2025. The meeting will be held at the Conference Room, 10th Floor, B8 Building, No. 188 Yizhou Road, Xuhui District, Shanghai, PRC. Shareholders will have the opportunity to vote on the resolutions as set out in the meeting notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL92cp7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","BK1230","HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"1197899525","title":"Shanghai Henlius (2696) Announces Renewal of Sinopharm Distribution Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=1197899525","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197899525?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:05","pubTimestamp":1764770708,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (2696) released an announcement regarding the renewal of the distribution partnership with Sinopharm Group Co. Ltd. (01099). The renewed framework agreement is set to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"2588041759","title":"Shareholders to Vote on Renewal of Sinopharm Distribution Collaboration at Shanghai Henlius Biotech Inc. EGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2588041759","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588041759?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:57","pubTimestamp":1764770263,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. will hold an Extraordinary General Meeting on December 31, 2025, where shareholders will vote on the renewal of the Sinopharm distribution collaboration, a continuing connected transaction. The Independent Board Committee has issued a recommendation regarding the proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL1C0xBk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1230","BK1161","02696","00656"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":-0.0541},{"period":"3month","weight":-0.2162},{"period":"6month","weight":0.1915},{"period":"1year","weight":1.5251},{"period":"ytd","weight":1.5464}],"compareEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":0.0231},{"period":"3month","weight":-0.0137},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3084},{"period":"ytd","weight":0.2862}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Henlius Biotech Inc is a China-based company principally engaged in biopharmaceutical research and development, biopharmaceutical services and biopharmaceutical production and sales. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The Company mainly operates its businesses in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.052523},{"month":2,"riseRate":0.666667,"avgChangeRate":0.108951},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016995},{"month":4,"riseRate":0.833333,"avgChangeRate":0.128587},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.016989}],"exchange":"SEHK","name":"HENLIUS","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HENLIUS,02696,HENLIUS股票,HENLIUS股票老虎,HENLIUS股票老虎国际,HENLIUS行情,HENLIUS股票行情,HENLIUS股价,HENLIUS股市,HENLIUS股票价格,HENLIUS股票交易,HENLIUS股票购买,HENLIUS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}